PubMed Health⌕ Search

Biomedical subjects

Michael Balls

Publications and source records attributed to Michael Balls.

At least 19 recordsLinked to original sources
PubMed2004

Progressing toward the reduction, refinement and replacement of laboratory animal procedures: thoughts on some encounters with Dr Iain Purchase.

A variety of encounters with Dr Iain Purchase over the last 25 years are reviewed in relation to their significance in terms of progress toward the reduction, refinement and replacement of animal procedures in toxicology and toxicity testing. Included are the work of the first FRAME Toxicity Committee and the FRAME International Alternatives Validation Scheme, the International Conferences on Practical In Vitro Toxicology and the foundation of Toxicology in Vitro, the work of an Institute of Medical Ethics working party on issues raised by animal experimentation and alternative approaches, the need for in vitro assays for chemical carcinogenesis based on the transformation of human cells, the problem presented by the human hazard potential of thousands of chemicals already in use before modern regulations for the registration of new chemicals came into force, and the importance of testing strategies with a focus on the integrated use of non-animal computer-based and in vitro test systems.

Animal Experimentation↗
PubMed2002

Future improvements: replacement in vitro methods.

Revolutions in thinking and practice are essential in regulatory toxicology if genuine protection of human beings and the environment is truly to be improved. New test development is the key: Tests should have greater relevance than the current animal procedures based on (1) a mechanistic understanding of the basis of the test method itself and of the toxic phenomenon of concern, (2) taking advantage of new developments in cell and molecular biology and computer systems of various kinds, and (3) a clear understanding of the value of good prediction models. In the not-too-distant future, current research in genomics, proteomics, and metabolomics should provide opportunities for the development of valuable new tests. An inescapable requirement of tests intended to be used for regulatory purposes is validation (i.e., an independent assessment of relevance and reliability for stated purposes according to internationally agreed-upon criteria). However, there is no standard validation scheme; a case-by-case approach is essential. It is important to take advantage of experience, which reveals that prevalidation makes formal validation studies faster, less expensive, and more likely to succeed, and that the procedures for independent assessment used by the European Centre for the Validation of Alternative Methods (ECVAM) and the Interagency Coordinating Committee for the Validation of Alternative Methods (ICCVAM) are effective in practice.

Animal Testing Alternatives↗
PubMed2002

The establishment of ECVAM and its progress since 1993.

The background to the establishment of ECVAM in 1991 is summarised, and progress made since 1993 is briefly reviewed in relation to 12 recommendations made at the ECVAM Opening Symposium in 1994 and to statements on tests for chemicals and biologicals endorsed by the ECVAM Scientific Advisory Committee since 1997.

Animal Testing Alternatives↗
PubMed2002

The principles of validation and the ECVAM validation process.

The validation of a test method is the process by which the relevance and reliability of the method are assessed for a particular purpose. It is an essential stage in the evolution of the method from its development to its acceptance and application for regulatory purposes. The principles according to which alternative tests should be validated have been agreed at an international level, although the actual process by which the validation process is conducted varies between different validation authorities. This paper summarises the principles of alternative test development and validation, and describes how the principles have been applied to the validation of in vitro tests by ECVAM.

Animal Testing Alternatives↗
PubMed2002

ECVAM's activities on biologicals.

This paper summarises key activities initiated and the progress achieved between April 1993 and June 2002 in implementing the Three Rs in one of ECVAM's priority areas - the production and quality control of biologicals. These have included: organising nine key workshops; financially supporting and/or participating in a number of prevalidation and/or validation studies; financial contributions and sponsorship to relevant international workshops, symposia and conferences; and financial support for the compilation of manuals and expert reports, and training in test methods. The paper complements the papers of Hendriksen et al. and Cussler et al. included in these proceedings.

Animal Testing Alternatives↗
PubMed2002

The future of ECVAM: a personal perspective.

Progress made in the practical application of the validation process is summarised, and some of the remaining problems are considered. Highlights of the first ten years of ECVAM are reviewed, andECVAM's activities as a route of communication on the Three Rs are discussed. Finally, some suggestions are made for maintaining ECVAM's momentum in the future, especially in relation to the challenge and opportunity for alternative methods afforded by the new EU Chemicals Policy.

Animal Testing Alternatives↗
PubMed2001

[Good cell culture practice (GCCP)--an initiative for standardization and quality control of in vitro studies. The establishment of an ECVAM Task Force on GCCP].

Cultured human and animal cells are increasingly used as the basis for simplified, direct test systems that have the potential to be more controllable and more reproducible than in vivo test systems. However, if a biological test system is simplified to fundamental levels then it is paramount that the essential components of such a reduced systems are closely defined and reproducible. Thus, minimal requirements for quality standards in cell and tissue culture have to be defined. It is the aim of this GCCP initiative to establish principles for standardisation, rationalisation, and international harmonisation of cell and tissue culture laboratory practices. Therefore, in analogy to Good Laboratory Practice (GLP), a Good Cell Culture Practice (GCCP) was initiated at the 3rd World Congress on Alternatives and Animal Use in the Life Sciences, Bologna, 29. August-2. September 1999. This "Bologna Statement on Good Cell Culture Practice" was presented, discussed, and refined in a Workshop, and a final version was approved at the closing ceremony of the Congress by the scientific audience. Based on the Bologna Statement, an ECVAM Task Force on GCCP was initiated, that is chaired by Thomas Hartung and Sandra Ceocke, in which experts in the field should elaborate minimal requirements for quality standards in cell culture. It is the intention of the GCCP Guidelines to encourage consensus among all concerned with the use of in vitro systems, in order to establish and maintain best laboratory practices, to promote effective quality control systems, to facilitate education and training, to support journal editors, and to help any authorities who need to interpret and apply conclusions based on in vitro data.

Animal Testing Alternatives↗
PubMed1998

[Use of transgenic animals in the European Union]

Transgenic animals present unique possibilities for medical, agricultural and fundamental research, and as a means of producing valuable pharmaceutical and nutrient products. Their use has increased dramatically in recent years and is set to increase further in the near future. It has been claimed that transgenic animals might allow reduction and refinement in animal use, via more-precise gene targeting in breeding programmes. However, these objectives are threatened by transgenic procedures which may promote greater animal use, more-varied applications, and the greater likelihood of animal suffering. Current legislation on animal experimentation, for example, Directive 86/609/EU, was passed and implemented before the full implications of transgenesis were recognised. For this reason, ECVAM organised a workshop which was held in Southwell, Nottinghamshire, UK, on 7-11 April 1997. The aim of this workshop was to reach a consensus on a set of guidelines designed to assist regulatory authorities in their decision-making process. The conclusions of the workshop are subdivided into general considerations, proposals to use transgenic animals, production and use of transgenic animals, specific considerations relating to animals used as basic research/disease models, animals used in testing for toxicity and carcinogenicity, and transgenic farm animals. 14 recommendations have been derived from these conclusions and should make an important contribution to ensuring that the interests and welfare of animals are given due respect. They demonstrate a willingness by scientists to respond to public concerns and they should facilitate a consistent, harmonised and equitable regulatory approach within the EU.

Journal Article↗
PubMedDate not supplied

ECVAM's contributions to the implementation of the Three Rs in the production and quality control of biologicals.

A summary is presented of the activities initiated, and the progress achieved, between April 1993 and December 2001 in implementing the Three Rs in one of the main priority areas of the European Centre for the Validation of Alternative Methods (ECVAM) - the production and quality control of biologicals. These have included organising eight key workshops, and financial contributions to, and sponsorship of, relevant international workshops, symposia and conferences. Noteworthy activities include financial support and/or participation in a number of prevalidation and validation studies. These involved alternative methods for the batch potency testing of: human tetanus vaccines; human and veterinary tetanus antisera and immunoglobulin; rabies vaccines; Leptospira hardjo vaccines; Clostridium perfringens vaccines; and erysipelas vaccines. They also involved a cell culture test for specific toxicity testing of diphtheria toxoid vaccines. In addition, ECVAM funded a study on the use of humane endpoints for vaccine quality control tests involving severe suffering, such as the potency testing of erysipelas, rabies and pertussis vaccines. ECVAM has also contributed financially to the compilation of manuals and expert reports, and to training in test methods. Following the report of an ECVAM Task Force, ECVAM financially supported the prevalidation of some in vitro methods for the potency testing of a recombinant hormone. A proposal is presented for promotion of regulatory acceptance, and suggestions are made for possible future activities.

Animal Testing Alternatives↗
PubMedDate not supplied

Follow-up to the ECVAM prevalidation study on in vitro tests for acute skin irritation. The European Centre for the Validation of Alternative Methods Skin Irritation Task Force report 2.

The European Centre for the Validation of Alternative Methods (ECVAM) Skin Irritation Task Force was established in 1996, to review the status of the development and validation of alternative tests for skin irritation and corrosion, and to identify appropriate non-animal tests for predicting human skin irritation that were sufficiently well-developed to be prevalidated and validated by ECVAM. The EpiDerm method, based on a reconstituted human skin model, was proposed as being sufficiently well advanced to enter a prevalidation (PV) study. Based on a review of test protocols, prediction models (PMs), and data submitted by test developers on ten specified chemicals, with 20% sodium lauryl sulphate as a reference standard, the task force recommended the inclusion of four other tests: EPISKIN and PREDISKIN, based on reconstituted human epidermis or on human skin; the non-perfused pig-ear test, based on pig skin; and the skin integrity function test (SIFT), with ex vivo mouse skin. The prevalidation study on these methods was funded by ECVAM, and took place during 1999-2000. The outcome of the PV study was that none of the methods was ready to enter a formal validation study, and that the protocols and PMs of the methods had to be improved in order to increase their predictive abilities. Improved protocols and PMs for the EpiDerm and EPISKIN methods, the pig ear test, and the SIFT were presented at an extended Task Force meeting held in May 2001. It was agreed that, in the short term, the performance of the revised and harmonised EpiDerm and EPISKIN methods, as well as the modified SIFT, should be evaluated in a further study with a new set of 20 test chemicals. In addition, it was decided that the SIFT and the pig ear test would be compared to see if common endpoints (transepidermal water loss, methyl green-pyronine stain) could be identified.

Animal Testing Alternatives↗